Donald Trump has announced a significant expansion of his prescription drug platform, TrumpRx, promising to boost the availability of medications under his discount program nearly sevenfold. Earlier this year, experts had voiced concerns about the limited selection of drugs on the site, which seemed to cater to a narrow group of patients. However, in a recent speech, Trump revealed plans to add over 600 affordable generic medications to TrumpRx, claiming it would serve as a central resource for consumers to find the lowest possible prescription costs.
Trump highlighted that TrumpRx would offer some of the most competitive prices on prescriptions already used by millions of Americans. In some instances, he noted, the discounted generics available through the site might be priced even lower than the out-of-pocket costs with insurance. The expansion also includes new tools, such as a feature that connects patients with the cheapest pharmacy nearby or allows them to have discounted prescriptions delivered directly to their homes.
At the event, Joe Gebbia, Trump’s chief design officer and co-founder of Airbnb, introduced a new price-comparison tool on the TrumpRx website. He explained that consumers could now easily compare the prices of medications, akin to how one might compare hotels, Airbnbs, or even sports tickets. Additionally, the website now features a section called “Presidential Deals,” showcasing some of the most affordable brand-name drugs available in the country. This allows consumers to search for brand-name medications and see how they stack up against generic alternatives.
Despite the enhancements to TrumpRx, some experts remain skeptical about its effectiveness for many patients. Sean Sullivan, a professor of health economics and policy and former dean of pharmacy at the University of Washington, previously commented that consumers might find cheaper versions of these medicines through insurance, pharmacies, or cash pay services like Cost Plus Drugs instead of the deals from TrumpRx. Rena Conti from Boston University’s Questrom School of Business echoed these sentiments, pointing out the complexities of the American healthcare system and how TrumpRx might add to that complexity rather than simplify it.